GPT and metabolic dysfunction-associated steatotic liver disease: Additionally, another meta-analysis of 10 randomized controlled trials (544 NAFLD subjects) concerning the benefit of supplemental VitD in NAFLD found that VitD improved the levels of glycemic control and liver injury markers, including serum fasting glucose (FBG), homeostasis model assessment of insulin resistance (HOMA-IR), alanine aminotransferase (ALT) and triglyceride [10].